The SVP of Dynavax (NASDAQ: DVAX) is Selling Shares

By Carrie Williams

Today, the SVP of Dynavax (NASDAQ: DVAX), David Novack, sold shares of DVAX for $8,100.

The company has a one-year high of $24.45 and a one-year low of $5. Currently, Dynavax has an average volume of 1.56M.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $29.4, reflecting a -44.6% downside.

The insider sentiment on Dynavax has been negative according to 14 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company’s development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.